Female Cancers
1632 clinical trials
20 cell line models
9 approved drugs
Female Cancers
Molecular Synopsis
Drugs and clinical candidates

9 drugs have received FDA approval for Female Cancers:

  • Bevacizumab
  • Bleomycin Sulfate
  • Mechlorethamine Hydrochloride
  • Niraparib
  • Olaparib

251 drugs have a clinical trial registered for Female Cancers.

1715 compounds have been tested in Female Cancers (1465 <= 500nM potency).

Sources: cancer.gov, clinicaltrials.gov, ChEMBL.

Clinical trials
There are 1632 clinical trials for Female Cancers, 873 of which have one or more drug interventions, 759 with no drug intervention.
Cell line models

There are 20 Cell Line Models for Female Cancers.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Female Cancers:
  • Uterine Cervical Neoplasms
  • Genital Neoplasms, Female
  • Retroperitoneal Neoplasms
  • Vaginal Neoplasms
  • Peritoneal Neoplasms
The following terms have been mapped from cancer.gov to Female Cancers:
  • Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used:As maintenance therapy in adults with recurrent disease who are having a complete or partial response to platinum chemotherapy
  • Vulvar cancer
  • Malignant pleural effusion, malignant pericardial effusion, and malignant peritoneal effusion
  • Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used in patients with stage III, stage IV, or recurrent disease. This use is approved for the Avastin brand of bevacizumab
  • Lesions that sometimes lead to anal, cervical, vaginal, or vulvar cancer